Influence of immunosuppression in patients with severe acute respiratory distress syndrome on veno-venous extracorporeal membrane oxygenation therapy

Jonathan Rilinger¹,² | Viviane Zotzmann¹,² | Xavier Bemtgen¹,² | Siegbert Rieg³ |
Paul M. Biever¹,² | Daniel Duerschmied¹,² | Torben Pottgiesser¹,² | Klaus Kaier⁴ |
Christoph Bode¹,² | Dawid L. Staudacher¹,² | Tobias Wengenmayer¹,²

¹Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
²Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany
³Division of Infectious Diseases, Department of Medicine II, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
⁴Institute of Medical Biometry and Statistics, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

Correspondence
Jonathan Rilinger, Department of Cardiology and Angiology I, Heart Center Freiburg University, University of Freiburg, Hugstetterstr. 55, 79106 Freiburg, Germany. Email: jonathan.rilinger@universitaetskliniken-freiburg.de

Abstract
Prognosis of patients suffering from acute respiratory distress syndrome (ARDS) is poor. This is especially true for immunosuppressed patients. It is controversial whether these patients should receive veno-venous extracorporeal membrane oxygenation (VV ECMO) while evidence on this topic is sparse. We report retrospective data of a single-center registry of patients with severe ARDS requiring ECMO support between October 2010 and June 2019. Patients were analyzed by their status of immunosuppression. ECMO weaning success and hospital survival were analyzed before and after propensity score matching (PSM). Moreover, ventilator free days (VFD) were compared. A total of 288 patients were analyzed (age 55 years, 67% male), 88 (31%) presented with immunosuppression. Survival rates were lower in immunosuppressed patients (27% vs. 53%, \( P < .001 \) and 27% vs. 48% after PSM, \( P = .006 \)). VFD (60 days) were lower for patients with immunosuppression (11.9 vs. 22.4, \( P < .001 \)), and immunosuppression was an independent predictor for mortality in multivariate analysis. Hospital survival was 20%, 14%, 35%, and 46% for patients with oncological malignancies, solid organ transplantation, autoimmune diseases, and HIV, respectively. In this analysis immunosuppression was an independent predictor for mortality. However, there were major differences in the weaning and survival rates between the etiologies of immunosuppression which should be considered in decision making.

KEYWORDS
acute respiratory distress syndrome, extracorporeal membrane oxygenation, immunosuppression, outcome

1 | BACKGROUND

Veno-venous extracorporeal membrane oxygenation (VV ECMO) may improve survival in patients with severe acute respiratory distress syndrome (ARDS).¹⁻³ Thus, there was a substantial increase in the use of ECMO therapy over the recent years.⁴ However, the outcome is strongly dependent on the underlying etiology of ARDS and the concomitant diseases and conditions, especially the presence of immunosuppression.⁵⁻⁹
Immunosuppressed patients with respiratory failure are at high risk which is reflected by high mortality rates. Hospital mortality in case of respiratory failure ranges from 17% to 72%.\textsuperscript{10-15} The high mortality contributes to the underlying disease itself as well as to a more severe course of ARDS when immunosuppression is present.\textsuperscript{16}

Previous trials showed an association of immunosuppression and increased mortality in patients with ARDS treated with ECMO.\textsuperscript{5,6,17} Therefore, the use of ECMO in patients with immunosuppression is deemed critical, and the ELSO guidelines consider major pharmacologic immunosuppression as a relative contraindication for the use of ECMO support.\textsuperscript{18}

However, the number of patients with immunosuppression is increasing steadily,\textsuperscript{19} as the spectrum of immunosuppressive therapies as well as the volume of solid organ transplantsations are increasing over the last years.\textsuperscript{20,21} Thus, more patients with immunosuppression are admitted to the ICU because of respiratory failure\textsuperscript{22} and a large number is treated with ECMO in case of ARDS despite underlying immunosuppression. In recently published trials, 20%-30% of ECMO patients showed some kind of immunosuppression.\textsuperscript{2,5} Moreover, hospital survival of immunosuppressed non-ECMO patients with ARDS has improved over the years. However, mortality still remains high in case of severe ARDS (69%).\textsuperscript{23} Additionally, there is a large spectrum of immunosuppressive conditions with very different survival rates as shown in various non-ECMO ARDS trials.\textsuperscript{16}

Even if some studies, especially the IDEA study,\textsuperscript{7} examined the use of VV ECMO in immunosuppressed patients, evidence on outcome still is limited. In addition to the opportunity to add data of a large ECMO center treating immunosuppressed patients, this study also includes a control group of patients with VV ECMO support without immunosuppression. We therefore performed a retrospective analysis to investigate the influence of immunosuppression and its etiologies on hospital survival, ECMO weaning success as well as ventilator free days at 30 and 60 days in patients with severe ARDS requiring VV ECMO support at our center.

2 | PATIENTS AND METHODS

We report retrospective data of a single-center registry of patients with severe ARDS treated with VV ECMO. All patients treated at the Interdisciplinary Medical Intensive Care Unit at the Medical Center, University of Freiburg, Germany, between October 2010 and June 2019 were registered. Patient identity data derived from the registry were blinded, and the study plan was approved by the local ethics committee (EK-Freiburg 151/14). The need for informed consent of the subjects was waived by the local ethics committee.

2.1 | Study population

Our center treats a large number of hematoooncological patients and patients with autoimmune diseases. This leads to a high amount of patients with immunosuppression on our intensive care units (ICU), many of them requiring treatment for respiratory failure.

In this study, the status of immunosuppression was investigated and patients were divided into an “immunosuppression” and “no immunosuppression” group. The term immunosuppressed describes a reduced ability to fight infections and other diseases, which can be caused by underlying diseases and conditions as well as by drug therapy or treatment. Four subgroups of immunosuppression were defined: immunosuppression in cause of oncological malignancies (including hematologic malignancies and active solid tumors), caused by the disease itself or a related therapy (chemotherapy or hematopoietic stem cell transplantation (HSCT) within the last year) (oncological); immunosuppression in patients after solid organ transplantation (solid organ Tx); patients with autoimmune diseases and immunosuppressive therapies (cut off for steroids: ≥10 mg/day prednisolone equivalent) (autoimmune disease); and patients with immunosuppression caused by HIV (HIV).

In this study all patients suffered from severe ARDS. VV ECMO support was initiated in cases of severe hypoxic respiratory failure or CO\textsubscript{2}-retention despite mechanical ventilation (MV) as suggested by the ELSO guidelines.

Primary endpoints were successful ECMO weaning and hospital survival. In addition to the hospital survival rate, cumulative incidences of 60-day mortality were calculated using competing risk regression. Free from ECMO support and alive for at least 48 hours after decannulation was defined as successful ECMO weaning. Unsuccessful weaning was defined as the inability to explant the ECMO device because of persistent respiratory failure or death during ECMO support and the need for recannulation within 48 hours. Moreover, ventilator free days (VFDs, absence of invasive MV) were analyzed for the first 30 and 60 days, respectively. VFD’s were set to zero if the patient died within the first 30 or 60 days after ECMO implantation.

Furthermore, pulmonary pathogen spectrum ascertained by broncho alveolar lavage (BAL) and tracheal secretions (TS) was investigated.

To compare the patients’ disease severity, the RESP,\textsuperscript{6} SOFA,\textsuperscript{24} and APACHE-II\textsuperscript{25} scores as well as the Horowitz index (PaO\textsubscript{2}/FiO\textsubscript{2}) were analyzed at the time of ECMO initiation.

2.2 | ECMO center and ECMO management

Our institution features a 24/7 ECMO-center localized within a tertiary hospital with a 30-bed medical ICU.
Cannulations in our ECMO center are performed by two experienced intensivists and a perfusionist using Seldinger’s technique without primary surgical cut down. All members of the ECMO team can be gathered within 30 minutes. Typical numbers for veno-arterial and veno-venous cannulation are 65 and 45 per year, respectively. There is a 24/7 outreach team. For this research, only in-house cases were considered. As ECMO systems, either SCPC (Sorin Centrifugal Pump Console, LivaNova, London, UK) or Cardiohelp (Maquet Getinge Group, Rastatt, Germany) was used.

Cannulation was performed predominately via the jugular vein using a dual-lumen cannula (Avalon, Maquet, Rastatt, Germany). For patients without life threatening bleeding, anticoagulation was provided by intravenous unfractionated heparin aiming at a partial thromboplastin time 1.5 times upper normal limit. The management of vasopressors and fluid therapy was driven by clinical judgment of the ECMO experienced intensivist in charge and has been reported earlier.26

Treatment algorithms and standard operating procedures were subject to optimizations during the observational period, reflecting current state of the art recommendations and scientific knowledge.

Immunosuppression represents no absolute contraindication at our center. This is especially true for patients with respiratory failure in the context of active HIV or autoimmune diseases. Patients after solid organ transplantation are critically evaluated. Patients with an underlying oncological disease with a prognosis of >6 months are also evaluated for ECMO support in case of severe ARDS, depending on their clinical condition and comorbidities.

Whenever possible, spontaneous breathing modes like continuous positive pressure ventilation with pressure support were applied. Biphasic positive airway pressure (BIPAP) was the controlled MV mode that was used mostly at our institution. In very few patients, airway pressure release ventilation (APRV) was used, when considered beneficial. VV ECMO support was implemented in case of severe but potentially reversible respiratory failure, when lung-protective MV resulted in hypoxemia or hypercapnia. Lung-protective MV was defined as positive end expiratory pressure (PEEP) ≤ 15 cmH2O, plateau pressure ≤30 cmH2O, driving pressure ≤15 cmH2O, and FiO2 ≤ 50%.

After initiation of the VV ECMO support, invasivity of MV was reduced and ECMO flow was adjusted aiming for a peripheral oxygen saturation of 85%-90% and partial pressure arterial oxygen of approximately 50 mm Hg, respectively. Typical ventilator settings were as follows: PEEP 15 mm Hg, plateau pressure 25 cmH2O, FiO2 50%, and respiratory rate 10/minute. Details on ventilator management and prone positioning procedures have been described earlier.27

2.3 | Statistical analysis

Continuous variables are presented as median and interquartile range (IQR), whereas IQR is displayed as Q1-Q3. Categorical variables are presented as numbers and percentages. Results of VFD are presented as mean ± SD.28 Mann–Whitney U test was used for analysis of continuous variables, Pearson’s Chi-squared test, or Fisher’s exact test for categorical variables to investigate group differences depending on the status of immunosuppression. In addition, weaning success and survival of each subtype of immunosuppression was compared with the nonimmunosuppressed patients. Multivariate regression analysis was performed for univariate (dependent) predictors of hospital survival. Results are given as odds ratio ([OR], 95% confidence interval [CI]); a P value of ≤.05 was considered statistically significant. Propensity score matching was performed to adjust for disease severity and risk of death in the immunosuppression and nonimmunosuppression group using SPSS with a nearest neighbor matching algorithm using a caliper of 0.01. Matching was performed for variables with independent association to improved or reduced hospital survival in multivariate analysis (lung fibrosis, liver cirrhosis, and proof of pulmonary fungal infection) in all patients. In addition to the analysis of in-hospital mortality as a dichotomous endpoint, cumulative incidences of 60-day mortality were calculated using competing risk regression (Fine and Gray method) with discharge alive considered a competing event for the illustration of the time course of mortality for the patients in the two groups.29 Statistical calculations were performed using IBM SPSS statistics 25.0 (Armonk, NY: IBM Corp, 2017) and Stata Version 15.1 (Stata Corp, College Station, TX, USA).

3 | RESULTS

3.1 | Patients

A total of 288 patients with complete medical data could be analyzed (age 55 [42.5-64] years, 67% male). A total of 88 (30.6%) patients presented with immunosuppression (Figure 1). Pre-existing pulmonary disease was present in 30.2% of the patients (9% lung fibrosis, 4.9% long-term oxygen therapy [LTOT], Table 1).

Both groups showed a similar profile of age and sex. BMI was lower in patients with immunosuppression. There was no difference in terms of underlying pulmonary disease, except for a higher rate of lung fibrosis in the immunosuppression group (15.9% vs. 6%, P = .007). Patients with immunosuppression showed a significant lower rate of comorbidities like nicotine abuse, coronary artery disease, and a trend for less hypertension. Though, more patients with immunosuppression required chronic hemodialysis.
Horowitz index was higher in patients with immunosuppression. There was no difference in terms of duration of MV before ECMO implantation; average for both groups was 1 day. Patients without immunosuppression showed a higher rate of acute renal failure before ECMO.

APACHE II-score was higher in patients without immunosuppression (27 [22-32] vs. 24 [16-29], $P = .002$). Moreover, the RESP score was lower in patients with immunosuppression (0 [-2 to 2] vs. 2 [0-4], $P < .001$). A calculation of the RESP score without inclusion of immunosuppression showed identical results for both groups (2 [0-4], $P = .852$).

Patients with immunosuppression showed lower values of leukocytes, platelets, hemoglobin, hematocrit, and creatinine. ARDS was more often related to pneumonia and less often to aspiration in patients with immunosuppression.

Pulmonary pathogen spectrum revealed a high amount of viral and fungal infections in all patients (31.6% and 19.1%, respectively); 85% of pulmonary microbiological proofs were obtained by BAL. Patients with immunosuppression showed a different pulmonary pathogen spectrum, with more fungal (29.5% vs. 14.5%, $P = .003$) and less bacterial (22.7% vs. 50%, $P < .001$) infections.

3.3 Analysis of immunosuppression as an independent predictor for mortality

A univariate analysis of all patients showed an association between increased mortality and age, lung fibrosis, liver cirrhosis, immunosuppression, proof of pulmonary fungal infection, and absence of a pulmonary microbiological proof. Furthermore, proof of pulmonary bacterial infection was associated with decreased mortality (Additional file 1, Table E1).

A multivariate analysis of these factors revealed immunosuppression as an independent predictor for mortality (Odds ratio 0.42 [0.23-0.76], $P = .005$, Additional file 1, Figure E1). Moreover, lung fibrosis, liver cirrhosis and proof of pulmonary fungal infection were independent predictor for mortality.
# TABLE 1  Baseline characteristics

| Demographics                        | All (n = 288) | Immunosuppression (n = 88) | No immunosuppression (n = 200) | P value |
|-------------------------------------|---------------|---------------------------|--------------------------------|---------|
| **Age (years)**                     | 55 (42.5-64)  | 54.5 (39.3-65)            | 55 (45-63)                     | .756    |
| **Sex (male)**                      | 193 (67%)     | 56 (63.6%)                | 137 (68.5%)                    | .419    |
| **BMI (kg/m²)**                     | 24.4 (23.4-29.2) | 24 (21.8-27.5)           | 24.7 (23.5-30.1)               | .004    |
| **Underlying pulmonary disease**    | 87 (30.2%)    | 26 (29.5%)                | 61 (30.5%)                     | .871    |
| COPD                                | 25 (8.7%)     | 7 (8%)                    | 18 (9%)                        | .772    |
| Asthma                              | 16 (5.6%)     | 2 (2.3%)                  | 14 (7%)                        | .107    |
| Lung fibrosis                       | 26 (9%)       | 14 (15.9%)                | 12 (6%)                        | .007    |
| Cystic fibrosis                     | 7 (2.4%)      | 1 (1.1%)                  | 6 (3%)                         | .344    |
| LTOT                                | 14 (4.9%)     | 5 (5.7%)                  | 9 (4.5%)                       | .667    |
| Pulmonary hypertension              | 8 (2.8%)      | 3 (3.4%)                  | 5 (2.5%)                       | .665    |
| **Comorbidities**                   |               |                           |                                |         |
| Nicotine abuse                      | 98 (34%)      | 20 (22.7%)                | 78 (39%)                       | .007    |
| Hypertension                        | 98 (34%)      | 23 (26.1%)                | 75 (37.5%)                     | .061    |
| Diabetes mellitus                   | 39 (13.5%)    | 8 (9.1%)                  | 31 (15.5%)                     | .143    |
| CAD                                 | 36 (12.5%)    | 4 (4.5%)                  | 32 (16%)                       | .007    |
| Chronic renal failure               | 21 (7.3%)     | 9 (10.2%)                 | 12 (6%)                        | .204    |
| Chronic hemodialysis                | 2 (0.7%)      | 2 (2.3%)                  | 0 (0%)                         | .032    |
| Liver cirrhosis                     | 22 (7.6%)     | 6 (6.8%)                  | 16 (8%)                        | .728    |
| **Procedural characteristics**      |               |                           |                                |         |
| Oxygenation pre ECMO                |               |                           |                                |         |
| \( \text{FiO}_2 \) (%)             | 1 (0.8-1)     | 1 (0.7-1)                 | 1 (0.8-1)                      | .207    |
| Horowitz index (mm Hg)              | 70.9 (57.9-98.8) | 77.3 (60.1-123.6)        | 67.3 (55.5-90)                 | .002    |
| \( \text{D(A-a)O}_2 \) (mm Hg)     | 554 (418.5-598) | 538 (381-592.5)         | 557.5 (428-601)                | .139    |
| **Duration of MV before ECMO (days)**| 1 (0.2-3.3) | 0.8 (0.1-4.7)           | 1.1 (0.2-2.9)                  | .716    |
| <2 days                             | 178 (61.8%)   | 51 (58%)                  | 127 (63.5%)                    | .659    |
| 2-7 days                            | 70 (24.3%)    | 24 (27.3%)                | 46 (23%)                       | .032    |
| >7 days                             | 40 (13.9%)    | 13 (14.8%)                | 27 (13.5%)                     |         |
| Acute renal failure                 | 96 (33.3%)    | 20 (22.7%)                | 76 (38%)                       | .011    |
| **Scores**                          |               |                           |                                |         |
| SOFA score                          | 13 (11-15)    | 12.5 (10-15)              | 13 (11-15)                     | .489    |
| APACHE-II score                     | 26 (20-32)    | 24 (16-29)                | 27 (22-32)                     | .002    |
| RESP score                          | 1 (-1 to 3)   | 0 (-2 to 2)               | 2 (0-4)                        | <.001   |
| RESP score (without immunosuppression) | 2 (0-4)     | 2 (0-4)                   | 2 (0-4)                        | .852    |
| **Laboratory pre ECMO**             |               |                           |                                |         |
| Leukocytes (10^3/µL)                | 12.3 (6.7-19.2)| 8.9 (3.4-14.1)          | 14.2 (7.3-21.6)                | <.001   |
| Platelets (10^3/µL)                 | 157 (83-242)  | 112.5 (48-231.5)         | 175 (100-253)                  | <.001   |
| Hb (g/dL)                           | 9.9 (8.3-12.1)| 9.3 (8-10.7)             | 10.3 (8.4-12.8)                | <.001   |
| Hematocrit (%)                      | 30.3 (26.1-36.4)| 28.5 (24.9-32.9)       | 32.2 (26.8-38.4)               | .001    |
| Creatinine (mg/mL)                  | 1.3 (0.8-2.2) | 1 (0.7-1.7)              | 1.4 (0.9-2.6)                  | .001    |
| Urea (mg/dL)                        | 65 (39-110)   | 63 (36.5-108.5)          | 65 (39-111)                    | .664    |
| Bilirubin (mg/dL)                   | 0.8 (0.4-1.7) | 0.7 (0.4-1.4)            | 0.8 (0.4-1.8)                  | .434    |

(Continues)
### TABLE 1 (Continued)

| Demographics | All (n = 288) | Immunosuppression (n = 88) | No immunosuppression (n = 200) | P value |
|--------------|--------------|---------------------------|--------------------------------|---------|
| pH           | 7.2 (7.2-7.3)| 7.2 (7.1-7.3)             | 7.2 (7.2-7.3)                  | .550    |
| pO2 (mm Hg)  | 66.3 (57.9-77.3) | 71.1 (58.8-80.8)         | 64.5 (57.5-75.5)               | .026    |
| pCO2 (mm Hg) | 56 (46-72.5) | 53.3 (44.3-73.3)         | 56.5 (46.8-71.7)               | .414    |
| Lactate (mmol/L) | 1.9 (1.1-4.1) | 1.7 (1.1-3.2)           | 2.1 (1.2-4.7)                  | .166    |

### Causes of ARDS

|                  | All (n = 288) | Immunosuppression (n = 88) | No immunosuppression (n = 200) | P value |
|------------------|--------------|---------------------------|--------------------------------|---------|
| Pneumonia        | 205 (71.2%)  | 72 (81.8%)                 | 133 (66.5%)                    | .019    |
| Aspiration       | 25 (8.7%)    | 3 (3.4%)                   | 22 (11.1%)                     |         |
| Other injuries   | 58 (21.1%)   | 13 (14.8%)                 | 45 (22.4%)                     |         |

### Pulmonary pathogen spectrum

| Pathogen        | All (n = 288) | Immunosuppression (n = 88) | No immunosuppression (n = 200) | P value |
|-----------------|--------------|---------------------------|--------------------------------|---------|
| Bacterial       | 120 (41.7%)  | 20 (22.7%)                 | 100 (50%)                      | <.001   |
| Viral           | 91 (31.6%)   | 33 (37.5%)                 | 58 (29%)                       | .153    |
| Fungal          | 55 (19.1%)   | 26 (29.5%)                 | 29 (14.5%)                     | .003    |
| Pneumocystis jirovecii | 19 (6.6%) | 19 (21.6%) | 0 (0%) | <.001 |
| None detected   | 95 (33%)     | 32 (36.4%)                 | 63 (31.5%)                     | .419    |

Abbreviations: APACHE II score, acute physiology and chronic health evaluation; ARDS, acute respiratory distress syndrome; BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; D(A-a)O2, alveolar-arterial gradient of oxygen concentration; ECMO, extracorporeal membrane oxygenation; FiO2, fraction of inspired oxygen; LTOT, long-term oxygen therapy; MV, mechanical ventilation; RESP score, respiratory extracorporeal membrane oxygenation survival prediction; SOFA score, sequential organ failure assessment.

| TABLE 2 | Outcome and procedural characteristics |
|---------|----------------------------------------|
|         | All (n = 288) | Immunosuppression (n = 88) | No immunosuppression (n = 200) | P value |
| Weaning successful | 153 (53.1%) | 33 (37.5%) | 120 (60%) | <.001 |
| Hospital survival | 129 (44.8%) | 24 (27.3%) | 105 (52.5%) | <.001 |
| VFD (30 days) | 6.6 ± 9.6 | 4.0 ± 8.2 | 7.8 ± 9.9 | .001 |
| VFD (60 days) | 19.2 ± 23.1 | 11.9 ± 20.4 | 22.4 ± 23.6 | <.001 |
| ICU length of stay (days) | 13.4 (9-23.6) | 11.9 (7-20.3) | 14.1 (9.1-24.1) | .140 |
| ECMO duration (days) | 6.7 (3.9-12.3) | 6.2 (4-11.3) | 7.1 (3.9-12.8) | .346 |
| MV duration (days) | 12.4 (7.5-22.5) | 11.1 (5.2-19.9) | 13.9 (8.5-24.3) | .032 |
| Dual-lumen cannula | 244 (84.7%) | 71 (80.7%) | 173 (86.5%) | .206 |
| Primary non IMV ECMO | 22 (7.6%) | 14 (15.9%) | 8 (4%) | <.001 |
| Tracheostomy | 111 (38.5%) | 31 (35.2%) | 80 (40%) | .443 |
| Hemodialysis | 108 (37.5%) | 25 (28.4%) | 83 (41.5%) | .035 |

Note: Results of VFD are presented as mean ± SD. Abbreviations: ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IMV, invasive mechanical ventilation; MV, mechanical ventilation; VFD, ventilator free days.

### 3.4 Propensity score matching analysis

Eighty-eight propensity score matched pairs (176 patients, Figure 1; Additional file 1, Table E2) could be analyzed. Successful ECMO weaning rate was 37.5% versus 56% (P = .015) with and without immunosuppression, respectively. Moreover, survival rate was lower in patients with immunosuppression (27.3% vs. 47.6%, P = .006).

Cumulative incidence of 30 and 60 days in-hospital death of patients with versus without immunosuppression was 70% versus 48% and 73% versus 51%, respectively (P = .002, Figure 2B).

### 3.5 Etiologies of immunosuppression

Forty-one patients (46.5%, Figure 1) showed underlying oncological malignancies. Most patients were treated for hematological disease (61% leukemia, 29.2% lymphoma, and 9.8% with solid cancer). Twelve (29.2%)
patients had received HSCT within the last year before index hospitalization.

Seven patients (8%) received immunosuppressive therapy after solid organ Tx (lung [3x], kidney [3x], liver [1x]). Twenty-nine patients (33%) had immunosuppression due to an autoimmune disease. Eleven patients (12.5%) presented with immunosuppression caused by HIV infection. HIV was diagnosed during index hospitalization. Therefore, all HIV patients were without previous antiretroviral treatment.

Subgroups of immunosuppression differed in baseline characteristics like age and sex (Additional file 1, Table E3). Rate of underlying pulmonary disease ranged from zero (HIV) to 48.3% (autoimmune disease).

There was no difference in the duration of MV before ECMO initiation between the oncological, solid organ Tx, and autoimmune disease group (0.1-1 day) except in the HIV group (5.3 days). Moreover, there were differences in pulmonary pathogen spectrum with a very high rate of *Pneumocystis jirovecii* infections (PJP) in HIV patients (72.7%), for instance.

The subgroups of immunosuppression showed distinct differences in the survival rates. Hospital survival for patients of the oncological and solid organ Tx group were significantly lower compared to patients without immunosuppression (19.5% and 14.3% vs. 52.5%, \( P < .001 \) and \( P = .047 \), respectively, Figure 3). Survival in patients with hematopoietical and solid malignancies was similar (18.9% vs. 25%, \( P = 1.0 \)).

There was a trend for a lower survival rate in patients of the autoimmune disease group (34.5%, \( P = .070 \)). Patients of the HIV group showed a comparable survival to the patients without immunosuppression (45.5%, \( P = .761 \)).

For patients of the oncological, autoimmune disease, and HIV group ECMO weaning rates were slightly higher than the survival rates (Figure 3). Patients of the solid organ Tx group showed a high weaning rate of 57.1% compared to low survival rate of 14.3%.

4 | DISCUSSION

In this trial, immunosuppression in patients with ARDS and ECMO support was strongly associated with decreased survival. Multivariate analysis confirmed immunosuppression as an independent risk factor for reduced survival. Furthermore, immunosuppression was associated with a markedly reduced rate of VFDs after 30 and 60 days.

However, subgroup analysis revealed large differences in weaning and survival rates for the underlying etiologies of immunosuppression.

When comparing patients with and without immunosuppression, it is particularly important to consider further comorbidities as well as initial disease severity. Interestingly, clinical characteristics of patients with immunosuppression did not differ from the other patients in terms of age, sex, and underlying pulmonary disease, except of a higher rate of lung fibrosis in the immunosuppression group. In contrast to that, immunosuppressed patients showed fewer other comorbidities. Moreover, immunosuppressed and nonimmunosuppressed patients differed significantly in blood count and in pulmonary pathogen spectrum. Leukocytes, platelets, hemoglobin, and hematocrit were lower in the immunosuppression group, setting these patients to a higher risk of death, as each of these parameters by itself is associated
with increased mortality in ICU\textsuperscript{24,25} and ECMO patients.\textsuperscript{7} Especially, low platelet counts are associated with an increased risk for hemorrhage.\textsuperscript{30}

In ARDS patients the pulmonary pathogen spectrum is of great interest, with fungal infections increasing mortality.\textsuperscript{23} In this study, the rate of fungal infections was higher in the immunosuppressed group and fungal infections appeared as an independent predictor for survival.

An overall survival rate of only one out of four in immunosuppressed patients seems to be extremely low. On the other hand, survival of patients with severe ARDS and immunosuppression is significantly limited even when ECMO support is not required, as shown by a post hoc analysis of the LUNG SAFE study. Mortality rates in immunosuppressed versus immunocompetent patients were 46\% and 31\%, respectively.\textsuperscript{22} Azoulay et al reported a
survival rate of 44% in a mixed ARDS cohort suffering from malignancies, solid organ transplants, or drug-related immunosuppression.\(^\text{15}\)

However, immunosuppressed patients who survived their acute lung failure have a positive midterm prognosis. Schmidt et al showed that the 6-month survival rate of immunosuppressed ECMO patients was nearly the same compared to ICU survival (30% vs. 34%).\(^\text{7}\)

Therefore, a detailed analysis of the underlying etiologies of immunosuppression appears to be of particular importance in order to identify the patients who will benefit most from this invasive and resource intense therapy.

Importantly, patients with HIV showed a markedly superior outcome in terms of ECMO weaning and survival compared to the other etiologies of immunosuppression. These patients were younger and had no underlying pulmonary diseases. Nevertheless, they showed average results in the SOFA, APACHE-II, and RESP score and the longest duration of MV to ECMO implantation. In addition, there was a very high rate of PJP infections, which are typically associated with a very high mortality, except in HIV ECMO patients.\(^\text{31}\)

A large study investigating HIV patients (n = 2584) receiving MV due to respiratory failure showed a hospital survival rate of 55%.\(^\text{32}\) The survival rate of HIV patients requiring ECMO therapy in our cohort was 46%, which is quite encouraging considering that ECMO support was necessary. In summary, these patients showed a favorable outcome and ECMO support definitely should not be withheld in cases of severe ARDS.

Patients of the autoimmune disease group presented with the second highest survival rate of the immunosuppressed subgroups. This is surprising because these patients showed a high rate of underlying pulmonary diseases (especially lung fibrosis) and the lowest RESP score. Therefore, our results are in contrast to the study of Na et al, showing a considerably lower survival rate in 24 ECMO patients receiving steroids or immunosuppressant’s (nononcological and not for solid organ transplantation) of only 21%.\(^\text{33}\)

There was a noticeable difference between the ECMO weaning and the survival rate of patients in the solid organ Tx group. The weaning rate was comparable to patients without immunosuppression, but almost every patient died in the further course of the hospital stay, indicating that survival in these patients maybe is more related to the underlying disease than to the ARDS itself. Therefore, indication for ECMO support in these patients should be taken with care. However, it has to be considered that three of the seven solid organ Tx patients had received lung transplantation.

Patients with underlying oncological disease were the largest subgroup in this analysis (90% of them with hematoomcological malignancies). These patients showed the highest SOFA and APACHE-II score, reflecting severe organ failure. Hospital survival rates were noticeably low and even below the reported rates of Azoulay et al in non-ECMO ARDS patients with malignancies (31%).\(^\text{23}\) Astonishingly, Na et al even reported 100% mortality in 18 ECMO ARDS patients with hematoomcological malignancies.\(^\text{33}\)

Hence, patients with oncological underlying disease are a very special cohort within the group of immunosuppressed patients showing a particularly poor prognosis. However, even if the prognosis of these seriously ill patients is limited due to their underlying disease and the severe respiratory failure, 20% survived their hospital stay. Moreover, Azoulay et al reported that 80% of ICU survivors with hematologic malignancies had no health-related quality of life alterations (physical and mental health similar to that of the overall cancer population) after discharge.\(^\text{34}\)

### 4.1 Limitations

This is a retrospective observational study and therefore contains the risk of selection and reporting bias. Therefore, despite using propensity score matching for outcome analysis, there still might be remaining confounders. Moreover, this is a single-center report and specific processes may influence the presented results. Together, due to these limitations, our findings should be considered as hypothesis-generating and should not prompt clinical decision-making. Moreover, ECMO-related complications were not assessed in this study, so influence of platelet levels on bleeding events could not be determined.

### 5 Conclusion

In this analysis immunosuppression was strongly associated with increased hospital mortality. However, there were major differences in the weaning and survival rates between the etiologies of immunosuppression. The exclusion of an immunosuppressed patient from ECMO support should therefore be critically evaluated especially in regards to the underlying diseases.

### Ethics Approval and Consent to Participate

The protocol was approved by our institution's ethical committee (EK-Freiburg 151/14).

### Conflict of Interest

The authors declare that they have no competing interests.

### Author Contributions

All authors approved the final version of the manuscript. 

*Study design:* Rilinger, Wengenmayer 

*Data collection:* Rilinger, Wengenmayer
Data analysis and interpretation: Rilinger, Zottmann, Bemtgen, Rieg, Biever, Duerschmied, Pottgiesser, Kaier, Bode, Staudacher, Wengenmayer

Drafted the manuscript: Rilinger, Wengenmayer

Revised the manuscript for important intellectual content: Zottmann, Bemtgen, Rieg, Biever, Duerschmied, Pottgiesser, Kaier, Bode, Staudacher

DATA AVAILABILITY STATEMENT

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

ORCID
Jonathan Rilinger https://orcid.org/0000-0001-9333-3629

REFERENCES

1. Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanan MM, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009;374:1351–63.
2. Combes A, Hajage D, Capellier G, Demoule A, Lavoue S, Guervilly C, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med. 2018;378:1965–75.
3. Munshi L, Falke A, Goligher E, Pham T, Uleryk EM, Fan E. Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis. Lancet Respir Med. 2019;7:163–72.
4. Karagianidis C, Brodie D, Strassmann S, Stoelben E, Philipp A, Bein T, et al. Extracorporeal membrane oxygenation: evolving epidemiology and mortality. Intensive Care Med. 2016;42:889–96.
5. Schmidt M, Zogheib E, Roze H, Repesse X, Lebretot G, Luyt CE, et al. The PRESERVE mortality risk score and analysis of long-term outcomes after extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. Intensive Care Med. 2013;39:1704–13.
6. Schmidt M, Bailey M, Sheldrake J, Hodgson C, Aubron C, Rycus PT, et al. Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. the extracorporeal membrane oxygenation survival prediction (RESP) score. Am J Respir Crit Care Med. 2014;189:1374–82.
7. Schmidt M, Schellongowski P, Patroniti N, Taccone FS, Reis Miranda D, Reuter J, et al. Six-month outcome of immunocompromised severe ARDS patients rescued by ECMO. An international multicenter retrospective study. Am J Respir Crit Care Med. 2018;197:1297–307.
8. Jackel M, Rilinger J, Lang CN, Zottmann V, Kaier K, Stachon P, et al. Outcome of acute respiratory distress syndrome requiring extracorporeal membrane oxygenation in Covid-19 or influenza: a single-center registry study. Artif Organs. 2020. https://doi.org/10.1111/aor.13865.
9. Kim HS, Ha SO, Han SJ, Kim HS, Lee SH, Jung KS, et al. Extracorporeal membrane oxygenation support in trauma versus nontrauma patients with noninfectious acute respiratory failure. Artif Organs. 2017;41:431–9.
10. Garcia JB, Lei X, Wierda W, Cortes JE, Dickey BF, Evans SE, et al. Pneumonia during remission induction chemotherapy in patients with acute leukemia. Ann Am Thorac Soc. 2013;10:432–40.
11. Azoulay E, Fieux F, Moreau D, Thiery G, Rousselot P, Parrot A, et al. Acute monocytic leukemia presenting as acute respiratory failure. Am J Respir Crit Care Med. 2003;167:1329–33.
12. Specchia G, Pastore D, Carluccio P, Mele G, Montagna MT, Liso A, et al. Pneumonia in acute leukemia patients during induction therapy: experience in a single institution. Leuk Lymphoma. 2003;44:97–101.
13. Azoulay E, Thiery G, Chevret S, Moreau D, Darmon M, Bergeron A, et al. The diagnosis of acute respiratory failure in critically ill cancer patients. Medicine. 2004;83:360–70.
14. Roca O, de Aciliu MG, Caralt B, Sacanelli J, Masclans JR, ICU Collaborators. Humidified high flow nasal cannula supportive therapy improves outcomes in lung transplant recipients readmitted to the intensive care unit because of acute respiratory failure. Transplantation. 2015;99:1092–8.
15. Azoulay E, Pickkers P, Soares M, Perner A, Rello J, Bauer PR, et al. Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study. Intensive Care Med. 2017;43:1808–19.
16. Azoulay E, Mokart D, Kouatchet A, Demoule A, Lemiaile V. Acute respiratory failure in immunocompromised adults. Lancet Respir Med. 2019;7:173–86.
17. Enger T, Philipp A, Videm V, Lubnow M, Wahba A, Fischer M, et al. Prediction of mortality in adult patients with severe acute lung failure receiving veno-venous extracorporeal membrane oxygenation: a prospective observational study. Crit Care. 2014;18:R67.
18. Extracorporeal Life Support Organization (ELSO). Guidelines for Adult Respiratory Failure, V 1.4. 2017 Aug [cited 2020 Feb 3]. Available from: https://www.elso.org/Portals/0/ELSO%20Guidelines%20For%20Adult%20Respiratory%20Failure%201_4.pdf
19. Harpaz R, Dahl RM, Dooling KL. Prevalence of immunosuppression among US adults, 2013. JAMA. 2016;316:2547–8.
20. Weyand CM, Goronzky JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371:50–7.
21. Israni AK, Zaun D, Hadley N, Rosenendale JD, Schaaffhausen C, McKinney W, et al. OPTN/SRTR 2018 annual data report: deceased organ donation. Am J Transplant. 2020;20 Suppl 1:509–41.
22. Cortegiani A, Madotto F, Gregoretti C, Bellani G, Laffey JG, Pham T, et al. Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database. Crit Care. 2018;22:157.
23. Azoulay E, Lemiaile V, Mokart D, Pene F, Kouatchet A, Perez P, et al. Acute respiratory distress syndrome in patients with malignancies. Intensive Care Med. 2014;40:1106–14.
24. Raith EP, Udy AA, Bailey M, McGloughlin S, MacIsaac C, Bellomo R, et al. Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFAs score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA. 2017;317:290–300.
25. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.
26. Staudacher DL, Gold W, Biever PM, Bode C, Wengenmayer T. Early fluid resuscitation and volume therapy in venoarterial extracorporeal membrane oxygenation. J Crit Care. 2017;37:130–5.
27. Rilinger J, Zottmann V, Bemtgen X, Schumacher C, Biever PM, Duerschmied D, et al. Prone positioning in severe ARDS requiring extracorporeal membrane oxygenation. Crit Care. 2020;24:397.
28. Yehya N, Harhay MO, Curley MAQ, Schoenfeld DA, Reeder RW. Reappraisal of ventilator-free days in critical care research. Am J Respir Crit Care Med. 2019;200:828–36.
29. Resche-Rigon M, Azoulay E, Chevret S. Evaluating mortality in intensive care units: contribution of competing risks analyses. Crit Care. 2006;10:R5.
30. Thiagarajan RR, Barbaro RP, Rycus PT, McMullan DM, Conrad SA, Fortenberry JD, et al. Extracorporeal life support organization registry international report 2016. ASAIO J. 2017;63:60–7.
31. Rilinger J, Staudacher DL, Rieg S, Duerschmied D, Bode C, Wengenmayer T. Extracorporeal membrane oxygenation in Pneumocystis jirovecii pneumonia: outcome in HIV and non-HIV patients. Crit Care. 2019;23:356.
32. Barbier F, Roux A, Canet E, Martel-Samb P, Aegerter P, Wolff M, et al. Temporal trends in critical events complicating HIV infection: 1999-2010 multicentre cohort study in France. Intensive Care Med. 2014;40:1906–15.
33. Na SJ, Park SH, Hong SB, Cho WH, Lee SM, Cho YJ, et al. Clinical outcomes of immunocompromised patients on extracorporeal membrane oxygenation support for severe acute respiratory failure. Eur J Cardiothorac Surg. 2020;57:788–95.

34. Azoulay E, Mokart D, Pene F, Lambert J, Kouatchet A, Mayaux J, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium—a groupe de recherche respiratoire en reanimation onco-hematologique study. J Clin Oncol. 2013;31:2810–8.

SUPPORTING INFORMATION
Additional Supporting Information may be found online in the Supporting Information section.

How to cite this article: Rilinger J, Zotzmann V, Bemtgen X, et al. Influence of immunosuppression in patients with severe acute respiratory distress syndrome on veno-venous extracorporeal membrane oxygenation therapy. Artif Organs. 2021;45:1050–1060. https://doi.org/10.1111/aor.13954